- Home
- SBGI vs IOVA Comparison
SBGI vs IOVA Comparison
Compare SBGI & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- IOVA
- Stock Information
- Founded
- SBGI 1986
- IOVA 2007
- Country
- SBGI United States
- IOVA United States
- Employees
- SBGI N/A
- IOVA N/A
- Industry
- SBGI Broadcasting
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBGI Industrials
- IOVA Health Care
- Exchange
- SBGI Nasdaq
- IOVA Nasdaq
- Market Cap
- SBGI 886.6M
- IOVA 975.1M
- IPO Year
- SBGI 1995
- IOVA N/A
- Fundamental
- Price
- SBGI $15.92
- IOVA $2.47
- Analyst Decision
- SBGI Buy
- IOVA Buy
- Analyst Count
- SBGI 5
- IOVA 12
- Target Price
- SBGI $21.00
- IOVA $10.36
- AVG Volume (30 Days)
- SBGI 595.5K
- IOVA 20.9M
- Earning Date
- SBGI 11-05-2025
- IOVA 11-06-2025
- Dividend Yield
- SBGI 6.34%
- IOVA N/A
- EPS Growth
- SBGI N/A
- IOVA N/A
- EPS
- SBGI N/A
- IOVA N/A
- Revenue
- SBGI $3,337,000,000.00
- IOVA $250,425,000.00
- Revenue This Year
- SBGI N/A
- IOVA $65.15
- Revenue Next Year
- SBGI $9.50
- IOVA $58.47
- P/E Ratio
- SBGI N/A
- IOVA N/A
- Revenue Growth
- SBGI N/A
- IOVA 175.62
- 52 Week Low
- SBGI $11.89
- IOVA $1.64
- 52 Week High
- SBGI $18.46
- IOVA $9.70
- Technical
- Relative Strength Index (RSI)
- SBGI 55.53
- IOVA 57.23
- Support Level
- SBGI $14.52
- IOVA $2.09
- Resistance Level
- SBGI $17.88
- IOVA $2.55
- Average True Range (ATR)
- SBGI 0.88
- IOVA 0.24
- MACD
- SBGI -0.07
- IOVA 0.01
- Stochastic Oscillator
- SBGI 40.96
- IOVA 61.59
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.